NTRA
Natera Inc
NASDAQ · Biotechnology
$203.04
+5.96 (+3.02%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.88B | 1.35B | 5.49B | 5.13B | 5.06B |
| Net Income | -211,202,554 | -136,289,021 | 1.03B | 875.75M | 965.00M |
| EPS | — | — | — | — | — |
| Profit Margin | -11.2% | -10.7% | 18.8% | 17.1% | 19.1% |
| Rev Growth | +39.5% | +39.5% | +5.0% | +14.5% | +4.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 884.23M | 884.23M | 9.56B | 9.62B | 10.44B |
| Total Equity | 13.16B | 13.16B | 8.11B | 7.95B | 7.98B |
| D/E Ratio | 0.07 | 0.07 | 1.18 | 1.21 | 1.31 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -212,198,466 | -144,538,999 | 1.33B | 1.33B | 1.35B |
| Free Cash Flow | — | — | 838.86M | 778.23M | 1.13B |